1. Home
  2. ACRV vs ECOR Comparison

ACRV vs ECOR Comparison

Compare ACRV & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACRV
  • ECOR
  • Stock Information
  • Founded
  • ACRV 2018
  • ECOR 2005
  • Country
  • ACRV United States
  • ECOR United States
  • Employees
  • ACRV N/A
  • ECOR N/A
  • Industry
  • ACRV Medicinal Chemicals and Botanical Products
  • ECOR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ACRV Health Care
  • ECOR Health Care
  • Exchange
  • ACRV Nasdaq
  • ECOR Nasdaq
  • Market Cap
  • ACRV 41.7M
  • ECOR 38.5M
  • IPO Year
  • ACRV 2022
  • ECOR 2018
  • Fundamental
  • Price
  • ACRV $1.33
  • ECOR $5.27
  • Analyst Decision
  • ACRV Buy
  • ECOR Strong Buy
  • Analyst Count
  • ACRV 7
  • ECOR 2
  • Target Price
  • ACRV $17.40
  • ECOR $25.50
  • AVG Volume (30 Days)
  • ACRV 213.8K
  • ECOR 127.5K
  • Earning Date
  • ACRV 08-13-2025
  • ECOR 08-06-2025
  • Dividend Yield
  • ACRV N/A
  • ECOR N/A
  • EPS Growth
  • ACRV N/A
  • ECOR N/A
  • EPS
  • ACRV N/A
  • ECOR N/A
  • Revenue
  • ACRV N/A
  • ECOR $27,700,000.00
  • Revenue This Year
  • ACRV N/A
  • ECOR $23.21
  • Revenue Next Year
  • ACRV $1,037.93
  • ECOR $44.10
  • P/E Ratio
  • ACRV N/A
  • ECOR N/A
  • Revenue Growth
  • ACRV N/A
  • ECOR 30.16
  • 52 Week Low
  • ACRV $1.05
  • ECOR $4.16
  • 52 Week High
  • ACRV $10.16
  • ECOR $19.49
  • Technical
  • Relative Strength Index (RSI)
  • ACRV 51.00
  • ECOR 44.35
  • Support Level
  • ACRV $1.27
  • ECOR $4.80
  • Resistance Level
  • ACRV $1.42
  • ECOR $5.58
  • Average True Range (ATR)
  • ACRV 0.08
  • ECOR 0.54
  • MACD
  • ACRV 0.00
  • ECOR -0.00
  • Stochastic Oscillator
  • ACRV 55.32
  • ECOR 38.13

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

About ECOR electroCore Inc.

electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.

Share on Social Networks: